- Home
- SEIC vs EXEL Comparison
SEIC vs EXEL Comparison
Compare SEIC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEIC
- EXEL
- Stock Information
- Founded
- SEIC 1968
- EXEL 1994
- Country
- SEIC United States
- EXEL United States
- Employees
- SEIC N/A
- EXEL N/A
- Industry
- SEIC Investment Bankers/Brokers/Service
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEIC Finance
- EXEL Health Care
- Exchange
- SEIC Nasdaq
- EXEL Nasdaq
- Market Cap
- SEIC 10.7B
- EXEL 10.0B
- IPO Year
- SEIC N/A
- EXEL 2000
- Fundamental
- Price
- SEIC $85.12
- EXEL $34.69
- Analyst Decision
- SEIC Hold
- EXEL Buy
- Analyst Count
- SEIC 5
- EXEL 17
- Target Price
- SEIC $75.20
- EXEL $32.18
- AVG Volume (30 Days)
- SEIC 685.4K
- EXEL 1.7M
- Earning Date
- SEIC 01-29-2025
- EXEL 02-04-2025
- Dividend Yield
- SEIC 1.08%
- EXEL N/A
- EPS Growth
- SEIC 23.19
- EXEL 441.02
- EPS
- SEIC 4.15
- EXEL 1.55
- Revenue
- SEIC $2,052,819,000.00
- EXEL $2,081,598,000.00
- Revenue This Year
- SEIC $13.09
- EXEL $20.59
- Revenue Next Year
- SEIC $7.60
- EXEL $1.50
- P/E Ratio
- SEIC $20.51
- EXEL $22.41
- Revenue Growth
- SEIC 8.53
- EXEL 17.31
- 52 Week Low
- SEIC $61.58
- EXEL $19.20
- 52 Week High
- SEIC $87.25
- EXEL $36.97
- Technical
- Relative Strength Index (RSI)
- SEIC 67.49
- EXEL 49.52
- Support Level
- SEIC $84.39
- EXEL $34.58
- Resistance Level
- SEIC $87.25
- EXEL $36.22
- Average True Range (ATR)
- SEIC 1.31
- EXEL 0.77
- MACD
- SEIC -0.04
- EXEL -0.29
- Stochastic Oscillator
- SEIC 64.02
- EXEL 14.61
About SEIC SEI Investments Company
SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $99 billion in assets under management. As of December 2023, SEI (including LSV) manages, administers, or advises about $1.4 trillion in assets.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.